Related Experiment Videos
CDNF Protein Therapy in Parkinson's Disease
Henri J Huttunen1,2, Mart Saarma3
11 Herantis Pharma Plc, Espoo, Finland.
Cell Transplantation
|April 6, 2019
Summary
Cerebral dopamine neurotrophic factor (CDNF) shows promise for Parkinson's disease therapy by promoting neuron survival. Unlike other growth factors, CDNF targets endoplasmic reticulum stress, offering a novel therapeutic approach currently in clinical trials.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Neurotrophic factors (NTFs) are crucial for neuron survival and differentiation, with therapeutic potential in neurodegenerative diseases.
- Delivering NTFs to target tissues remains a significant challenge for effective therapies.
- Previous NTF clinical trials for Parkinson's disease (PD) include GDNF, NRTN, and PDGF-BB.
Purpose of the Study:
- To introduce cerebral dopamine neurotrophic factor (CDNF) as a novel therapeutic candidate for Parkinson's disease.
- To highlight CDNF's unique structural and mechanistic properties compared to other NTFs.
- To review the progress of CDNF in preclinical and clinical studies for PD.
Main Methods:
- Investigated CDNF's neurorestorative effects in animal models of PD.
- Assessed the safety profile of intraputamenal CDNF administration in toxicology studies.
- Currently evaluating CDNF in a phase I-II clinical trial for PD patients.
Main Results:
- Recombinant human CDNF demonstrated significant neurorestorative effects in PD animal models.
- Preclinical studies indicated a favorable safety profile for CDNF.
- CDNF is structurally and mechanistically distinct, modulating the unfolded protein response (UPR).
Conclusions:
- CDNF represents a novel class of NTFs with potential for treating chronic degenerative diseases like PD.
- Its unique mechanism targeting ER stress and UPR offers a new therapeutic avenue.
- Ongoing clinical trials will further elucidate CDNF's efficacy and safety in PD patients.